Literature DB >> 15539383

Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumors.

Andreas Helfenstein1, Sven O Frahm, Matthias Krams, Wolf Drescher, Reza Parwaresch, Joachim Hassenpflug.   

Abstract

The distinction between chondrosarcoma and enchondroma is difficult, and no reliable immunohistochemical or molecular methods are available. Differentiation is important because the therapeutic consequences range from radiologic followup to radical operation. We studied 17 chondrosarcomas (12 grade 1) and compared them with 14 enchondromas immunohistochemically by using the monoclonal antibodies Ki-MCM6 (minichromosome maintenance protein 6), Ki-S5 (Ki-67), and Ki-S2 (repp86), in addition to the established clinical criteria. In comparison with the other markers, Ki-MCM6 proved more effective at identifying proliferative activity in grade 1 chondrosarcomas. The MCM6 labeling index correlated with tumor grade and was significantly increased in grade 1 chondrosarcomas compared with enchondromas. The 5 cases of progressive chondrosarcoma also had a significantly higher MCM6 labeling index than the nonprogressive cases. Furthermore, by means of the MCM6 labeling index, many cases of progressive disease were recognized among those of uncertain malignant potential, justifying their classification as low-grade chondrosarcomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539383     DOI: 10.1309/G638-TKNN-G2CJ-UXWL

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  19 in total

1.  In malignant cartilagenous tumors, immunohistochemical expression of procollagen PC1CP peptide is higher and that of PC2CP lower than in benign cartilaginous lesions.

Authors:  Camille Delaunay-Lemarie; Jean-Baptiste Vincourt; Béatrice Marie; Shyue-Fang Battaglia-Hsu; Stéphanie Etienne; François Sirveaux; Phi Linh Nguyen Thi; Jacques Magdalou; Jean-Michel Vignaud; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2015-06-23       Impact factor: 4.064

2.  MCM7 expression is a promising predictor of recurrence in patients surgically resected for meningiomas.

Authors:  Theo L Winther; Sverre H Torp
Journal:  J Neurooncol       Date:  2016-11-21       Impact factor: 4.130

3.  Prognostic significance of MCM6 expression in gastrointestinal stromal tumor.

Authors:  Young-Ran Shim; Aeri Kim; Mi-Jin Gu
Journal:  Int J Clin Exp Pathol       Date:  2021-12-15

4.  Extended intralesional treatment versus resection of low-grade chondrosarcomas.

Authors:  Chad Aarons; Benjamin K Potter; Sheila C Adams; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

5.  Gene and protein expressions induced by 17beta-estradiol and parathion in cultured breast epithelial cells.

Authors:  Gloria M Calaf; Debasish Roy
Journal:  Mol Med       Date:  2007 May-Jun       Impact factor: 6.354

6.  Surgical treatment of grade I central chondrosarcoma.

Authors:  Davide Donati; Simone Colangeli; Marco Colangeli; Claudia Di Bella; Franco Bertoni
Journal:  Clin Orthop Relat Res       Date:  2009-08-29       Impact factor: 4.176

7.  Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1.

Authors:  Z G Gulzar; J K McKenney; J D Brooks
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

8.  High MCM6 Expression as a Potential Prognostic Marker in Clear-cell Renal Cell Carcinoma.

Authors:  Nu-Ri Jang; Jina Baek; Younghwii Ko; Phil Hyun Song; Mi-Jin Gu
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

9.  Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma.

Authors:  C Schrader; D Janssen; W Klapper; J-U Siebmann; P Meusers; G Brittinger; M Kneba; M Tiemann; R Parwaresch
Journal:  Br J Cancer       Date:  2005-10-17       Impact factor: 7.640

10.  Expression of human MCM6 and DNA Topo II alpha in craniopharyngiomas and its correlation with recurrence of the tumor.

Authors:  Jianguo Xu; Sizhong Zhang; Chao You; Siqing Huang; Bowen Cai; Xiaojie Wang
Journal:  J Neurooncol       Date:  2007-04-05       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.